

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) A polypeptide comprising more than one S3 peptides.
2. (Original) The polypeptide of claim 1 wherein the S3 peptides are in tandem repeat.
3. (Previously presented) The polypeptide of claim 1 comprising 2 to 10 S3 peptides.
4. (Previously presented) The polypeptide of claim 1 comprising two S3 peptides.
5. (Previously presented) The polypeptide of claim 1 comprising three S3 peptides.
6. (Previously presented) The polypeptide of claim 1 comprising four S3 peptides.
7. (Previously presented) The polypeptide of claim 1 comprising eight S3 peptides.
8. (Previously presented) The polypeptide of claim 1 wherein at least two of the S3 peptides are separated by a linking sequence.
9. (Original) The polypeptide of claim 8 wherein at least one of the linking sequence is cleavable by protease.
10. (Original) The polypeptide of claim 8 wherein at least one of the linking sequence is cleavable by acid digestion.
11. (Original) The polypeptide of claim 10 wherein the at least one linking sequence comprises Asp-Pro.
12. (Previously presented) The polypeptide of claim 1 consisting of the S3 peptides.

Amdt. dated December 30, 2008

Reply to Office Communication of December 17, 2008

Reply to Office Action of August 28, 2008

13. (Original) The polypeptide of claim 6 which is rS3-4mer (SEQ ID N0 : 9).
14. (Previously presented) The polypeptide of claim 1 tagged with a detectable label.
15. (Original) S3 peptide tagged with a detectable label.
16. (Previously presented) The polypeptide of claim 15 wherein the label is detectable by fluorescence.

Claims 17-31 (Canceled).

32. (Previously presented) The polypeptide of claim 1 immobilized on a solid medium.
33. (Original) The peptide of claim 15 immobilized on a solid medium.
34. (Previously presented) The polypeptide of claim 33 wherein the solid medium is agarose.

Claim 35 (Canceled).

36. (Previously presented) A commercial package comprising the polypeptide of claim 1 and instructions for its use in detecting LPS-containing bacteria in a sample.
37. (Previously presented) A commercial package comprising the polypeptide of claim 1 and instructions for its use in treating endotoxaemia or sepsis.
38. (Previously presented) A commercial package comprising the polypeptide of claim 32 and instructions for its use for removing LPS or LPS-containing bacteria from a sample.